Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | GALR2 | O43603 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766494 | 0.87 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL4246885 | 0.86 | ALDH1A1 (0.45) | ALDH1A1PDE4BSMN1; SMN2NPSR1POLB | |
| SCHEMBL4398405 | 0.81 | SMN1; SMN2 (0.50) | ALDH1A1PDE4BSMN1; SMN2NPC1RAB9A | |
| SCHEMBL30846439 | 0.81 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL27314724 | 0.81 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL574989 | 0.81 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL4067929 | 0.80 | MEN1 (0.42) | ALDH1A1PDE4BSMN1; SMN2POLBHPGD | |
| SCHEMBL12861401 | 0.80 | THRB (0.42) | ALDH1A1PDE4BSMN1; SMN2NPSR1POLB | |
| SCHEMBL17042260 | 0.79 | NPSR1 (0.55) | ALDH1A1PDE4BSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL14031475 | 0.79 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2NPC1RAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421230-B2 | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-23 | — | — | US | disclosed |
| CN-115335380-B | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-4100408-B1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4100408-B1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230114683-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-13 | — | — | US | disclosed |
| EP-4100408-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115335380-A | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2021158498-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158498-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230114683-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK2 | ALDH1A1 3424/4885PDE4B 1223/4885SMN1; SMN2 2554/4885 |
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | ALDH1A1 4166/4885PDE4B 1291/4885SMN1; SMN2 3299/4885 |
| US-12421230-B2 | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | IRAK4, IRAK3, IRAK2 | ALDH1A1 3424/4885PDE4B 1223/4885SMN1; SMN2 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.